ID POLG_EC11G Reviewed; 2195 AA. AC P29813; Q66785; DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 4. DT 15-JAN-2008, entry version 80. DE Genome polyprotein [Contains: Protein VP0 (VP4-VP2); Protein VP4 DE (Virion protein 4) (P1A); Protein VP2 (Virion protein 2) (P1B); DE Protein VP3 (Virion protein 3) (P1C); Protein VP1 (Virion protein 1) DE (P1D); Picornain 2A (EC 3.4.22.29) (Protein 2A) (P2A); Protein 2B DE (P2B); Protein 2C (EC 3.6.1.15) (P2C); Protein 3A (P3A); Protein 3B DE (P3B) (VPg); Picornain 3C (EC 3.4.22.28) (Protease 3C) (P3C); RNA- DE directed RNA polymerase 3D-POL (EC 2.7.7.48) (P3D-POL)]. OS Echovirus 11 (strain Gregory). OC Viruses; ssRNA positive-strand viruses, no DNA stage; Picornavirales; OC Picornaviridae; Enterovirus. OX NCBI_TaxID=31705; OH NCBI_TaxID=9606; Homo sapiens (Human). RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC RNA]. RX MEDLINE=95282506; PubMed=7762294; DOI=10.1016/0168-1702(94)00104-K; RA Dahllund L., Nissinen L., Pulli T., Hyttinen V.P., Stanway G., RA Hyypiae T.; RT "The genome of echovirus 11."; RL Virus Res. 35:215-222(1995). RN [2] RP NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 822-2195. RX MEDLINE=91011360; PubMed=2170575; RA Auvinen P., Hyypiae T.; RT "Echoviruses include genetically distinct serotypes."; RL J. Gen. Virol. 71:2133-2139(1990). RN [3] RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 1-859. RC STRAIN=Isolate clinical EV11-207; RX PubMed=12097583; DOI=10.1128/JVI.76.15.7694-7704.2002; RA Stuart A.D., McKee T.A., Williams P.A., Harley C., Shen S., RA Stuart D.I., Brown T.D., Lea S.M.; RT "Determination of the structure of a decay accelerating factor-binding RT clinical isolate of echovirus 11 allows mapping of mutants with RT altered receptor requirements for infection."; RL J. Virol. 76:7694-7704(2002). CC -!- FUNCTION: Capsid proteins VP1, VP2, VP3 and VP4 form a closed CC capsid enclosing the viral positive strand RNA genome. VP4 lies on CC the inner surface of the protein shell formed by VP1, VP2 and VP3. CC All the three latter proteins contain a beta-sheet structure CC called beta-barrel jelly roll. Together they form an icosahedral CC capsid (T=3) composed of 60 copies of each VP1, VP2, and VP3, with CC a diameter of approximately 300 Angstroms. VP1 is situated at the CC 12 fivefold axes, whereas VP2 and VP3 are located at the quasi- CC sixfold axes (By similarity). CC -!- FUNCTION: VP0 precursor is a component of immature procapsids (By CC similarity). CC -!- FUNCTION: Protein 2A is a cysteine protease that is responsible CC for the cleavage between the P1 and P2 regions. It cleaves the CC host translation initiation factor EIF4G1, in order to shut down CC the capped cellular mRNA transcription (By similarity). CC -!- FUNCTION: Protein 2B affects membrane integrity and cause an CC increase in membrane permeability (By similarity). CC -!- FUNCTION: Protein 2C associates with and induces structural CC rearrangements of intracellular membranes. It displays RNA- CC binding, nucleotide binding and NTPase activities (By similarity). CC -!- FUNCTION: Protein 3A, via its hydrophobic domain, serves as CC membrane anchor. It also inhibits endoplasmic reticulum-to-Golgi CC transport (By similarity). CC -!- FUNCTION: Protein 3C is a cysteine protease that generates mature CC viral proteins from the precursor polyprotein. In addition to its CC proteolytic activity, it binds to viral RNA, and thus influences CC viral genome replication. RNA and substrate bind co-operatively to CC the protease (By similarity). CC -!- FUNCTION: RNA-directed RNA polymerase 3D-POL replicates genomic CC and antigenomic RNA by recognizing replications specific signals CC (By similarity). CC -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate CC + RNA(n+1). CC -!- CATALYTIC ACTIVITY: Selective cleavage of Tyr-|-Gly bond in the CC picornavirus polyprotein. CC -!- CATALYTIC ACTIVITY: Selective cleavage of Gln-|-Gly bond in the CC poliovirus polyprotein. In other picornavirus reactions Glu may be CC substituted for Gln, and Ser or Thr for Gly. CC -!- CATALYTIC ACTIVITY: NTP + H(2)O = NDP + phosphate. CC -!- SUBCELLULAR LOCATION: Protein VP2: Virion. Cytoplasm (Potential). CC -!- SUBCELLULAR LOCATION: Protein VP3: Virion. Cytoplasm (Potential). CC -!- SUBCELLULAR LOCATION: Protein VP1: Virion. Cytoplasm (Potential). CC -!- SUBCELLULAR LOCATION: Protein 2B: Cytoplasmic vesicle membrane; CC Peripheral membrane protein; Cytoplasmic side (Potential). CC Note=Probably localizes to the surface of intracellular membrane CC vesicles that are induced after virus infection as the site for CC viral RNA replication. These vesicles are derived from the CC endoplasmic reticulum (By similarity). CC -!- SUBCELLULAR LOCATION: Protein 2C: Cytoplasmic vesicle membrane; CC Peripheral membrane protein; Cytoplasmic side (Potential). CC Note=Probably localizes to the surface of intracellular membrane CC vesicles that are induced after virus infection as the site for CC viral RNA replication. These vesicles are derived from the CC endoplasmic reticulum (By similarity). CC -!- SUBCELLULAR LOCATION: Protein 3A: Cytoplasmic vesicle membrane; CC Peripheral membrane protein; Cytoplasmic side (Potential). CC Note=Probably localizes to the surface of intracellular membrane CC vesicles that are induced after virus infection as the site for CC viral RNA replication. These vesicles are derived from the CC endoplasmic reticulum (By similarity). CC -!- SUBCELLULAR LOCATION: Protein 3B: Virion (Potential). CC -!- SUBCELLULAR LOCATION: Picornain 3C: Cytoplasm (Potential). CC -!- SUBCELLULAR LOCATION: RNA-directed RNA polymerase 3D-POL: CC Cytoplasmic vesicle membrane; Peripheral membrane protein; CC Cytoplasmic side (Potential). Note=Probably localizes to the CC surface of intracellular membrane vesicles that are induced after CC virus infection as the site for viral RNA replication. These CC vesicles are derived from the endoplasmic reticulum (By CC similarity). CC -!- PTM: Specific enzymatic cleavages in vivo by the viral proteases CC yield a variety of precursors and mature proteins. Polyprotein CC processing intermediates such as VP0 which is a VP4-VP2 precursor CC are produced. During virion maturation, non-infectious particles CC are rendered infectious following cleavage of VP0. This maturation CC cleavage is followed by a conformational change of the particle CC (By similarity). CC -!- PTM: VPg is covalently linked to the genomic RNA (By similarity). CC -!- PTM: Myristoylation of VP4 is required during RNA encapsidation CC and formation of the mature virus particle (By similarity). CC -!- SIMILARITY: Belongs to the picornaviruses polyprotein family. CC -!- SIMILARITY: Contains 2 peptidase C3 domains. CC -!- SIMILARITY: Contains 1 RdRp catalytic domain. CC -!- SIMILARITY: Contains 1 SF3 helicase domain. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; X80059; CAA56365.1; -; Genomic_RNA. DR EMBL; D10582; BAA01439.1; -; Genomic_RNA. DR PIR; A36642; GNNYEC. DR PDB; 1H8T; X-ray; 2.90 A; A=570-860, B=70-331, C=332-569, D=1-69. DR PDB; 2C8I; EM; 14.00 A; A/B/C/D=-. DR PDBsum; 1H8T; -. DR PDBsum; 2C8I; -. DR SMR; P29813; 861-1010, 862-1011, 1551-2195. DR MEROPS; C03.011; -. DR MEROPS; C03.020; -. DR InterPro; IPR003593; AAA+_ATPase_core. DR InterPro; IPR004004; Helicase/Pol/Pept_Calicivir. DR InterPro; IPR000605; Helicase_SF3_ssDNA/RNA_vir. DR InterPro; IPR014759; Helicase_SF3_ssRNA_vir. DR InterPro; IPR014838; P3A. DR InterPro; IPR000199; Pept_C3_picorn. DR InterPro; IPR000081; Peptidase_C3. DR InterPro; IPR011565; Peptidase_C3_2. DR InterPro; IPR003138; Pico_P1A. DR InterPro; IPR002527; Pico_P2B. DR InterPro; IPR001676; Picornavirus_capsid. DR InterPro; IPR001205; RNA_pol_P3D. DR InterPro; IPR007094; RNA_pol_PSvir. DR Pfam; PF08727; P3A; 1. DR Pfam; PF00548; Peptidase_C3; 1. DR Pfam; PF02226; Pico_P1A; 1. DR Pfam; PF00947; Pico_P2A; 1. DR Pfam; PF01552; Pico_P2B; 1. DR Pfam; PF00680; RdRP_1; 1. DR Pfam; PF00073; Rhv; 3. DR Pfam; PF00910; RNA_helicase; 1. DR PRINTS; PR00918; CALICVIRUSNS. DR ProDom; PD001125; Pept_C3_picorn; 1. DR ProDom; PD001306; Peptidase_C3_2; 1. DR ProDom; PD001274; Pico_P2B; 1. DR SMART; SM00382; AAA; 1. DR PROSITE; PS50507; RDRP_SSRNA_POS; 1. DR PROSITE; PS51218; SF3_HELICASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; ATP-binding; Capsid protein; Complete proteome; KW Covalent protein-RNA linkage; Cytoplasm; Cytoplasmic vesicle; KW Helicase; Host-virus interaction; Hydrolase; Lipoprotein; Membrane; KW Myristate; Nucleotide-binding; Nucleotidyltransferase; Phosphoprotein; KW Protease; RNA replication; RNA-binding; RNA-directed RNA polymerase; KW Thiol protease; Transferase; Virion. FT INIT_MET 1 1 Removed; by host (By similarity). FT CHAIN 2 331 Protein VP0 (Potential). FT /FTId=PRO_0000311058. FT CHAIN 2 69 Protein VP4 (Potential). FT /FTId=PRO_0000039703. FT CHAIN 70 331 Protein VP2 (Potential). FT /FTId=PRO_0000039704. FT CHAIN 332 569 Protein VP3 (Potential). FT /FTId=PRO_0000039705. FT CHAIN 570 861 Protein VP1 (Potential). FT /FTId=PRO_0000039706. FT CHAIN 862 1011 Picornain 2A (Potential). FT /FTId=PRO_0000039707. FT CHAIN 1012 1110 Protein 2B (Potential). FT /FTId=PRO_0000039708. FT CHAIN 1111 1439 Protein 2C (Potential). FT /FTId=PRO_0000039709. FT CHAIN 1440 1528 Protein 3A (Potential). FT /FTId=PRO_0000039710. FT CHAIN 1529 1550 Protein 3B (Potential). FT /FTId=PRO_0000039711. FT CHAIN 1551 1733 Picornain 3C (Potential). FT /FTId=PRO_0000039712. FT CHAIN 1734 2195 RNA-directed RNA polymerase 3D-POL FT (Potential). FT /FTId=PRO_0000039713. FT TOPO_DOM 2 1505 Cytoplasmic (Potential). FT TOPO_DOM 1506 1521 In membrane (Potential). FT TOPO_DOM 1522 2195 Cytoplasmic (Potential). FT DOMAIN 1215 1371 SF3 helicase. FT DOMAIN 1960 2076 RdRp catalytic. FT NP_BIND 1239 1246 ATP (Potential). FT ACT_SITE 882 882 For picornain 2A activity (By FT similarity). FT ACT_SITE 900 900 For picornain 2A activity (By FT similarity). FT ACT_SITE 971 971 For picornain 2A activity (By FT similarity). FT ACT_SITE 1590 1590 For picornain 3C activity (Potential). FT ACT_SITE 1621 1621 For picornain 3C activity (Potential). FT ACT_SITE 1697 1697 For picornain 3C activity (By FT similarity). FT SITE 69 70 Cleavage (Potential). FT SITE 331 332 Cleavage; by picornain 3C (Potential). FT SITE 861 862 Cleavage; by picornain 2A (Potential). FT SITE 1011 1012 Cleavage; by picornain 3C (Potential). FT SITE 1110 1111 Cleavage; by picornain 3C (Potential). FT SITE 1439 1440 Cleavage; by picornain 3C (Potential). FT SITE 1528 1529 Cleavage; by picornain 3C (Potential). FT SITE 1550 1551 Cleavage; by picornain 3C (Potential). FT SITE 1733 1734 Cleavage; by picornain 3C (Potential). FT MOD_RES 1531 1531 O-(5'-phospho-RNA)-tyrosine (By FT similarity). FT LIPID 2 2 N-myristoyl glycine; by host (By FT similarity). FT CONFLICT 823 827 RLCQY -> SYANT (in Ref. 2). FT STRAND 4 7 FT STRAND 26 29 FT HELIX 36 38 FT TURN 43 44 FT HELIX 50 52 FT TURN 53 53 FT STRAND 57 58 FT STRAND 83 87 FT TURN 88 89 FT STRAND 90 94 FT STRAND 100 102 FT TURN 103 104 FT TURN 113 115 FT STRAND 123 123 FT HELIX 126 128 FT TURN 129 129 FT STRAND 133 134 FT STRAND 138 140 FT TURN 142 143 FT STRAND 147 150 FT TURN 153 154 FT TURN 156 157 FT HELIX 159 167 FT STRAND 168 180 FT TURN 185 186 FT STRAND 188 197 FT TURN 198 198 FT STRAND 203 203 FT TURN 206 207 FT STRAND 210 210 FT HELIX 212 215 FT STRAND 222 223 FT STRAND 225 225 FT STRAND 233 233 FT STRAND 235 235 FT STRAND 238 238 FT HELIX 239 241 FT TURN 242 245 FT HELIX 248 253 FT STRAND 256 260 FT TURN 261 263 FT STRAND 266 271 FT STRAND 280 280 FT TURN 282 284 FT STRAND 285 285 FT STRAND 288 299 FT STRAND 308 324 FT TURN 339 342 FT TURN 346 347 FT STRAND 354 354 FT TURN 357 358 FT STRAND 370 371 FT STRAND 373 373 FT HELIX 374 378 FT TURN 379 379 FT STRAND 382 383 FT TURN 386 387 FT STRAND 389 389 FT TURN 390 391 FT TURN 393 394 FT HELIX 396 399 FT STRAND 401 405 FT TURN 409 410 FT STRAND 412 417 FT TURN 420 422 FT HELIX 424 427 FT TURN 428 428 FT HELIX 430 435 FT TURN 436 437 FT STRAND 438 442 FT STRAND 445 451 FT TURN 455 456 FT STRAND 458 466 FT HELIX 476 479 FT TURN 480 481 FT STRAND 483 488 FT STRAND 494 499 FT STRAND 508 509 FT TURN 515 516 FT STRAND 520 530 FT TURN 533 534 FT STRAND 538 547 FT TURN 549 550 FT STRAND 552 556 FT TURN 560 561 FT TURN 572 573 FT STRAND 582 582 FT STRAND 586 586 FT TURN 598 599 FT STRAND 600 601 FT HELIX 603 605 FT HELIX 613 616 FT STRAND 622 622 FT STRAND 627 627 FT HELIX 629 631 FT STRAND 632 632 FT HELIX 633 637 FT STRAND 641 649 FT HELIX 656 658 FT STRAND 659 663 FT HELIX 670 676 FT TURN 677 678 FT STRAND 679 696 FT STRAND 710 716 FT TURN 718 719 FT TURN 726 727 FT HELIX 729 732 FT STRAND 738 742 FT TURN 743 744 FT STRAND 749 752 FT STRAND 761 762 FT STRAND 767 768 FT TURN 771 772 FT STRAND 777 777 FT HELIX 779 782 FT STRAND 787 792 FT STRAND 801 819 FT STRAND 844 844 FT TURN 847 848 SQ SEQUENCE 2195 AA; 245407 MW; 1CFC5DF288831AF0 CRC64; MGAQVSTQKT GAHETGLNAS GSSIIHYTNI NYYKDAASNS ANRQEFSQDP GKFTEPVKDI MVKSLPALNS PSAEECGYSD RVRSITLGNS TITTQESANV VVGYGRWPEY LKDNEATAED QPTQPDVATC RFYTLESVTW ERDSPGWWWK FPDALKDMGL FGQNMYYHYL GRAGYTLHVQ CNASKFHQGC LLVVCVPEAE MGCSQVDGTV NEHGLSEGET AKKFSSTSTN GTNTVQTIVT NAGMGVGVGN LTIYPHQWIN LRTNNCATIV MPYINNVPMD NMFRHHNFTL MIIPFVPLDY SSDSSTYVPI TVTVAPMCAE YNGLRLSTSL QGLPVMNTPG SNQFLTSDDF QSPSAMPQFD VTPELNIPGE VQNLMEIAEV DSVVPVNNVE GKLDTMEVYR IPVQSGNHQS DQVFGFQVQP GLDSVFKHTL LGEILNYFAH WSGSIKLTFV FCGSAMATGK FLLAYAPPGA NAPKNRKDAM LGTHIIWDVG LQSSCVLCVP WISQTHYRLV QQDEYTSAGN VTCWYQTGIV VPAGTPTSCS IMCFVSACND FSVRLLKDTP FIEQTALLQG DVVEAVENAV ARVADTIGSG PSNSQAVPAL TAVETGHTSQ VTPSDTMQTR HVKNYHSRSE SSIENFLSRS ACVYMGGYHT TNTDQTKLFA SWTISARRMV QMRRKLEIFT YVRFDVEVTF VITSKQDQGS RLGQDMPPLT HQIMYIPPGG PIPKSVTDYA WQTSTNPSIF WTEGNAPPRM SIPFISIGNA YSNFYDGWSH FSQNGVYGYN TLNHMGQIYV RHVNGSSPLP MTSTVRMYFK PKHVKAWVPR PPRLCQYKNA STVNFTPTNV TDKRTSINYI PETVKPDLSN YGAFGYQSGA VYVVNYRVVN RHLATHTDWQ NCVWEDYNRD LLISTTTAHG CDVIARCRCS TGVYYCQSKG KHYPVNFEGP GLVEVQESEY YPKRYQSHVL LAAGFSEPGD CGGILRCEHG VIGIVTMGGE GVVGFADVRD LLWLEDDAME QGVKDYVEQL GNAFGSGFTN QICEQVNLLK ESLVGQDSIL EKSLKALVKI ISALVIVVRN HDDLITVTAT LALIGCTSSP WRWLKQKVSQ YYGIPMAERQ NNGWLKKFTE MTNSCKGMEW ISIKIQKFIE WLKVKILPEV REKHEFLNRL KQLPLLESQI ATIEQSAPSQ SDQEQLFSNV QYFAHYCRKY APLYASEAKR VFSLEKKMSN YIQFKSKCRI EPVCLLLHGS PGAGKSVATN LIGRSLAEKL NSSVYTLPPD PDHFDGYKQQ AVVIVDDLCQ NPDGKDVSLF CQMVSSVDFV PPMAALEEKG ILFTSLFVLA STNAGSINAP TVSDSRALAR RFHFDMNIEV ISMYSQNGKI NMPMSEKTCD EECCPVNFKR CCPLVCGKAI QFIDRRTQVR YSLDMLVTEM FREYNHRHSV GATLEALFQG PPIYREIKIS VAPETPPPPA IADLLKSVDS EAVREYCKEK GWLVPEVNST LQIEKHVSRA FICLQALTTF VSVAGIIYII YKLFAGFQGA YTGMPNQKPK VPTLRQAKVQ GPAFEFAVAM MKRNSSTVKT EYREFTMLGI YDRWAVLPRH AKPGPTILMN NQEVGVLDAK ELVDKDGTNL ELTLLKLNRN EKFRDIRGFL AKEEVEANQA VLAINTSKFP NMYIPVGQVT DYGFLNLGGT PTKRMLMSNF PTRAGQCGGV LMSTGKVLGI HVGGNGHQGF SAALLKHYFN DEQGEIEFIE SSKDAGFPII NTPSKTKLEP SVFHQVFEGD KEPAVLRNGD PRLKANFEEA IFSKYIGNVN THVDEYMLEA VDHYAGQLAT LDISTEPMRL EDAVYGTEGL EALDLTTSAG YPYVALGIKK RDILSRRTRD LTKLKECMDK YGLNLPMVTY VKDELRSADK VAKGKSRLIE ASSLNDSVAM RQTFGNLYRT FHLNPGIVTG SAVGCDPDLF WSKIPVMLDG HLIAFDYSGY DASLSPVWFA CLKLLLEKLG YTHKETNYID YLCNSHHLYR DKHYFERGGM PSGYSGTSMF NSMINNIIIR TLMLKVYKGI DLDQFRMIAY GDDVIASYPW PIDASLLAET GKGYGLIMTP ADKGECFNEV TWTNVTFLKR YFRADEQYPF LVHPVMPMKD IHESIRWTKD PKNTQDHVRS LCLLAWHNGE HEYEEFIRKI RSVPVGRCLT LPAFSTLRRK WLDSF //